39 Thus, combination therapy targeting CIB1 may prove to be a safe and durable strategy for treating triple-negative breast cancer and potentially other cancers.39 Our research highlights the value of CIB1 blockade as an effective candidate to overcome HCC resistance to lenvatinib. This evidence concerns the gene CIB1 and cancer.